Charles River Laboratories Intl. Inc (CRL) Director Robert J. Bertolini Sells 3,609 Shares

Charles River Laboratories Intl. Inc (NYSE:CRL) Director Robert J. Bertolini sold 3,609 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $110.22, for a total transaction of $397,783.98. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Charles River Laboratories Intl. Inc (CRL) traded down $0.34 during trading on Wednesday, reaching $110.31. 404,993 shares of the company traded hands, compared to its average volume of 376,250. The company has a market cap of $5,210.00, a P/E ratio of 26.97, a P/E/G ratio of 1.61 and a beta of 0.88. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. Charles River Laboratories Intl. Inc has a one year low of $77.31 and a one year high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. Charles River Laboratories Intl.’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.18 EPS. analysts anticipate that Charles River Laboratories Intl. Inc will post 5.14 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. YorkBridge Wealth Partners LLC boosted its holdings in Charles River Laboratories Intl. by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after buying an additional 891 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after buying an additional 548 shares during the period. Advisor Group Inc. boosted its holdings in shares of Charles River Laboratories Intl. by 159.4% during the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Charles River Laboratories Intl. by 12.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares during the last quarter. Finally, Riverhead Capital Management LLC boosted its holdings in shares of Charles River Laboratories Intl. by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the last quarter. 95.80% of the stock is owned by institutional investors.

A number of equities research analysts have recently issued reports on the stock. Argus assumed coverage on shares of Charles River Laboratories Intl. in a research report on Wednesday, December 13th. They set a “buy” rating and a $120.00 price objective for the company. SunTrust Banks reissued a “buy” rating and set a $113.00 price objective on shares of Charles River Laboratories Intl. in a research report on Friday, November 17th. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Robert W. Baird set a $117.00 price objective on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a research report on Monday, November 13th. Finally, ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Six investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Charles River Laboratories Intl. presently has an average rating of “Buy” and a consensus target price of $110.21.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/charles-river-laboratories-intl-inc-crl-director-robert-j-bertolini-sells-3609-shares.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply